Association between early suicidal trajectories in first-episode psychosis and 10-year follow-up: TIPS registry-linked study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Sherif M. Gohar
  • Wenche ten Velden Hegelstad
  • Bjørn Auestad
  • Ulrik Helt Haahr
  • Inge Joa
  • Jan Olav Johannessen
  • Tor Ketil Larsen
  • Stein Opjordsmoen
  • Bjørn Rishovd Rund
  • Jan Ivar Røssberg
  • Simonsen, Erik
  • Svein Friis
  • Ingrid Melle

Background: Although the risk of suicidality is high in first-episode psychosis, patterns and individual variability in suicidal thoughts and behaviours over time are under-researched. We aimed to identify early trajectories of suicidality over a 2-year follow-up, assess their baseline predictors, and explore associations between those trajectories and later suicidality. Methods: This longitudinal follow-up study was a part of the Early Treatment and Intervention in Psychosis (TIPS)study. Participants, linked to Norwegian and Danish death registries, were recruited from four catchment areas (665 000 inhabitants) in Norway and Denmark (both inpatient and outpatient). We included participants aged 15–65 years, with an intelligence quotient of more than 70, willing to give informed consent, and with a first episode of active psychotic symptoms. Individuals with comorbid neurological or endocrinal disorders, or those with contraindications to antipsychotics, were excluded. Growth mixture modelling was used to identify trajectories of suicidal thoughts and behaviours over the first 2 years. Multinomial logistic regression was applied to examine the baseline predictors of those trajectories and their associations with suicidality at 10-year follow-up. Findings: A total of 301 participants were recruited from Jan 1, 1997, to Dec 31, 2000. Of the 299 with completed suicidality data at baseline, 271 participated in 1-year follow-up, 250 in 2-year follow-up, 201 in 5-year follow-up, and 186 at 10-year follow-up. At baseline, 176 (58%) were male, 125 (42%) were female. The mean age was 27·80 years (SD 9·64; range 15–63). 280 (93%) participants were of Scandinavian origin. Four trajectories over 2 years were identified: stable non-suicidal (217 [72%]), stable suicidal ideation (45 [15%]), decreasing suicidal thoughts and behaviours (21 [7%]), and worsening suicidal thoughts and behaviours (18 [6%]). A longer duration of untreated psychosis (odds ratio [OR] 1·24, 95% CI 1·02–1·50, p=0·033), poorer premorbid childhood social adjustment (1·33, 1·01–1·73, p=0·039), more severe depression (1·10, 1·02–1·20, p=0·016), and substance use (2·33, 1·21–4·46, p=0·011) at baseline predicted a stable suicidal ideation trajectory. Individuals in the stable suicidal ideation trajectory tended to have suicidal thoughts and behaviours at 10-year follow-up (3·12, 1·33–7·25, p=0·008). Individuals with a worsening suicidal trajectory were at a higher risk of death by suicide between 2 and 10 years (7·58, 1·53–37·62, p=0·013). Interpretation: Distinct suicidal trajectories in first-episode psychosis were associated with specific predictors at baseline and distinct patterns of suicidality over time. Our findings call for early and targeted interventions for at-risk individuals with persistent suicidal ideation or deteriorating patterns of suicidal thoughts and behaviours, or both. Funding: Health West, Norway; the Norwegian National Research Council; the Norwegian Department of Health and Social Affairs; the National Council for Mental Health and Health and Rehabilitation; the Theodore and Vada Stanley Foundation; the Regional Health Research Foundation for Eastern Region, Denmark; Roskilde County, Helsefonden, Lundbeck Pharma; Eli Lilly; Janssen-Cilag Pharmaceuticals, Denmark; a National Alliance for Research on Schizophrenia and Depression Distinguished Investigator Award and The National Institute of Mental Health grant; a National Alliance for Research on Schizophrenia & Depression Young Investigator Award from The Brain & Behavior Research Foundation; Health South East; Health West; and the Regional Centre for Clinical Research in Psychosis.

OriginalsprogEngelsk
TidsskriftThe Lancet Psychiatry
Vol/bind10
Udgave nummer7
Sider (fra-til)528-536
Antal sider9
ISSN2215-0366
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
The The Early Treatment and Intervention in Psychosis Study (TIPS) study was funded by Health West, Norway (grant number 911369 to WtVH); The Norwegian National Research Council (grant numbers 133897/320 and 154642/320); The Norwegian Department of Health and Social Affairs and the National Council for Mental Health and Health and Rehabilitation in Rogaland County and Oslo County (grant numbers 1997/41 and 2002/306, to JOJ, SF, TKL, IM, and SO); The Theodore and Vada Stanley Foundation, the Regional Health Research Foundation for Eastern Region (Roskilde County, Denmark), Helsefonden, Lundbeck Pharma, Eli Lilly, and Janssen-Cilag Pharmaceuticals, all in Denmark (ES and UHH); a National Alliance for Research on Schizophrenia and Depression Distinguished Investigator Award and National Institute of Mental Health grant (grant number MH-01654 to TM); a National Alliance for Research on Schizophrenia & Depression from the The Brain & Behavior Research Foundation Young Investigator Award (to TKL); Health South East (grant number 2008001); Health West (grant number 200202797–65, to IJ); and the Regional Centre for Clinical Research in Psychosis (grant number 911313). We thank Thomas McGlashan, who has been a cornerstone in the TIPS study. He had a major role in planning and running the study and was principal investigator from the start of the study in 1997 until 2013.

Funding Information:
The The Early Treatment and Intervention in Psychosis Study (TIPS) study was funded by Health West, Norway (grant number 911369 to WtVH); The Norwegian National Research Council (grant numbers 133897/320 and 154642/320); The Norwegian Department of Health and Social Affairs and the National Council for Mental Health and Health and Rehabilitation in Rogaland County and Oslo County (grant numbers 1997/41 and 2002/306, to JOJ, SF, TKL, IM, and SO); The Theodore and Vada Stanley Foundation, the Regional Health Research Foundation for Eastern Region (Roskilde County, Denmark), Helsefonden, Lundbeck Pharma, Eli Lilly, and Janssen-Cilag Pharmaceuticals, all in Denmark (ES and UHH); a National Alliance for Research on Schizophrenia and Depression Distinguished Investigator Award and National Institute of Mental Health grant (grant number MH-01654 to TM); a National Alliance for Research on Schizophrenia & Depression from the The Brain & Behavior Research Foundation Young Investigator Award (to TKL); Health South East (grant number 2008001); Health West (grant number 200202797–65, to IJ); and the Regional Centre for Clinical Research in Psychosis (grant number 911313). We thank Thomas McGlashan, who has been a cornerstone in the TIPS study. He had a major role in planning and running the study and was principal investigator from the start of the study in 1997 until 2013.

Publisher Copyright:
© 2023 Elsevier Ltd

ID: 386494032